TABLE 1.

Clinical registered studies for diabetic cardiomyopathy targeting pyroptosis.

Registration time	Identifier	Phase	Study title	Conditions	Interventions	Status	Primary outcome measures
2012	NCT01752842	Unknown	Lipid Biomarkers for Diabetic Heart Disease	. Type 2 diabetes mellitus . Diabetes complications	Drug: fenofibrate Drug: placebo	Completed	Change in cardiac diastolic function as measured by E′ and fractional shortening percent
2019	NCT04200586	IV	The Effects of SGLTi on Diabetic Cardiomyopathy (SGLTi)	. Type 2 diabetes . Heart failure with reduced ejection fraction	Drug: dapagliflozin Drug: placebo	Active, not recruiting	Rate of change in myocardial T1 values with manganese enhanced cardiac MRI
2019	NCT01803828	IV	REmodelling in Diabetic CardiOmyopathy: Gender Response to PDE5i InhibiTOrs (RECOGITO)	. Diabetic cardiomyopathy . Diabetes mellitus type 2	Drug: tadalafil Drug: placebo	Completed	Change from baseline in left ventricular torsion
2019	NCT04141475	Unknown	Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy (CARDIALA)	. Diabetic cardiomyopathies	Drug: physiomance acide lipoïque gold Drug: placebo	Recruiting	Change of LVEF between before and after 12 weeks of treatment
2020	NCT04591639	IV	The DAPA-MEMRI Trial (DAPA-MEMRI)	. Heart failure . Diabetic cardiomyopathies	Drug: dapagliflozin Drug: placebo	Recruiting	Change in myocardial perfusion reserve index
2022	NCT04083339	III	Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy	. Diabetic cardiomyopathy	Drug: AT-001 Drug: placebo	Recruiting	Peak VO2 during cardio-pulmonary exercise test